|
|
|
Journal of Bacteriology, January 2004, p . 244-247, Vol . 186, No . 1
Necessity of Meningococcal
|
| ABSTRACT |
|---|
The growth of a
-glutamyl
aminopeptidase (GGT)-deficient Neisseria meningitidis strain
was much slower than that of the parent strain in rat cerebrospinal
fluid (CSF) and in a synthetic CSF-mimicking medium, and the growth
failure was suppressed by the addition of cysteine . These results
suggested that, in the environment of cysteine shortage,
meningococcal GGT provided an advantage for meningococcal
multiplication by supplying cysteine from environmental
-glutamyl-cysteinyl
peptides .
| TEXT |
|---|
Neisseria meningitidis is a gram-negative diplococcus pathogen
that colonizes the nasopharynx of humans as a unique host . It
sometimes spreads into the bloodstream, resulting in septicemia, and
subsequently induces meningitis when it reaches the cerebrospinal
fluid (CSF) (25) .
-Glutamyl
transpeptidase (GGT; EC 2.3.2.2) (also called
-glutamyl
aminopeptidase) catalyzes the hydrolysis of
-glutamyl
compounds . In Escherichia coli, it is speculated that GGT
contributes to the recycling of exogenous glutathione (
-glutamyl-cysteinyl-glycine
[GSH]) (21), and Helicobacter pylori GGT is
advantageous for the colonization of notobiotic piglets and mice (6,
13) . In N . meningitidis, GGT is used as an
identification marker (3, 27) .
However, the physiological function of meningococcal GGT has not been
studied . In the present study, we characterized the physiological
function of meningococcal GGT by using in vitro experimental models,
owing to the lack of appropriate animal models for meningococcal
diseases (1, 14) .
The ggt gene of N . meningitidis strain H44/76 (23)
was disrupted by the insertion of a spectinomycin resistance gene by
a method described previously (23), resulting in
HT1089 (H44/76
ggt::Spcr) .
The disruption of the ggt gene in HT1089 was confirmed by the
absence of GGT activity in HT1089 extract (data not shown) and
by Western blotting using anti-meningococcal GGT rabbit serum
(preparation of the antiserum will be described elsewhere) (Fig .
1) . In commonly used rich media (e.g., Trypticase soy broth
and GC medium [Becton Dickinson]), HT1089 grew as well as the
parent strain (data not shown) .
|
We first examined the role of meningococcal GGT by using in vitro
models as follows: (i) adhesion to or invasion into cultured human
umbilical vein endothelial cells (HUVEC) and epithelial cells (Hep-2
and A549 cells), (ii) survival against complements in normal human
sera, and (iii) growth in inactivated rat sera . No differences
between HT1089 and H44/76 for these phenotypes were observed (Fig.
2A and data not shown) .
|
CSF is a critical environment for the infection and multiplication of
bacteria that cause meningitis in humans . It has been shown that
Streptococcus pneumoniae multiplies in CSF after 24 h of
infection in the rat meningitis model (16) . We examined the
multiplication of N . meningitidis strains in CSF in vitro . For
this experiment, we used sterile, pooled, heat-inactivated rat
CSF instead of human CSF because the quality of the rat CSF can be
more easily controlled and the amounts of its components, such as
amino acids, are largely similar to those of human CSF (2,
9, 11, 12,
15, 28) . When N . meningitidis
strains were cultured in CSF, a growth defect of HT1089 was clearly
observed compared to its growth in heat-inactivated rat sera (Fig.
2) . This result strongly suggested that the
meningococcal GGT provided an advantage for meningococcal
multiplication in CSF .
In order to further analyze the mechanism of meningococcal growth
in CSF, we tried to monitor meningococcal growth in defined
neisserial medium mimicking CSF, which was called CSF-mimicking
medium (CMM) . The composition was based on that of the defined agar
medium for N . meningitidis (4) except that the
concentrations of five amino acids (L-glutamine,
500 µM; L-glutamate, 8 µM; L-glycine,
7 µM; L-arginine, 18 µM; and L-cysteine,
1 µM) and three
-glutamyl
peptides (
-glutamyl-glutamate,
30 µM;
-glutamyl-cysteine,
2 µM; and GSH, 1 µM) were almost equal to those in human CSF or rat
brain (7, 17) . Moreover, in this
study, 0.5% glucose and 0.1% lactate were added to CMM as carbon
sources at concentrations that were 10 times higher than the actual
concentrations in human CSF (20) to avoid the
effects of carbon starvation . In CMM, H44/76 could grow well but
HT1089 could not (Fig . 3A), which was consistent
with the results in rat CSF (Fig . 2B) . In CMM without the
three
-glutamyl
peptides (CMM-GGPs), even H44/76 could not grow (Fig .
3B) . These results indicated that the growth of N . meningitidis
in CMM was completely dependent on the GGT activity and the
presence of
-glutamyl
peptides . The growth defect of H44/76, but not HT1089, was recovered
in CMM-GGPs supplemented with 5 µM GSH or 5 µM
-Glu-Cys
(Fig . 3C and D), indicating that the GGT supplied
glutamate or cysteine from
-glutamyl-cysteinyl
peptides in CMM to support meningococcal growth . Further experiments
revealed that H44/76 and HT1089 grew well in CMM-GGPs supplemented
with 10 µM cysteine (Fig . 3E), while the addition of 100
µM glutamate could not suppress their growth failure (Fig .
3F) . These results indicated that the meningococcal growth
failure in CMM-GGPs was due to the shortage of cysteine and suggested
that the meningococcal GGT functioned to supply cysteine from
the environmental
-glutamyl-cysteinyl
peptides . Additionally, the growth failure of HT1089 was partially
suppressed by supplementation of 5 µM cysteine in CMM (Fig.
3G) and completely suppressed by the addition of 20
µM cysteine (Fig . 3H) . The dose-dependent
suppression also supported the idea that the growth failure of the
ggt
N . meningitidis strain in CMM was due to the shortage of
cysteine . Furthermore, it was also confirmed that the growth defect
of HT1089 in CSF was considerably ameliorated when cysteine was added
to the CSF (data not shown) . Taken together, all of the
above-mentioned results support the conclusion that meningococcal GGT
has a function to accelerate meningococcal multiplication by
releasing cysteine from
-glutamyl-cysteinyl
peptides in CMM and CSF .
|
Previous studies showed that cysteine is required for the growth of
N . meningitidis in synthetic media (4, 8),
and in the present study, N . meningitidis strain H44/76 showed
an auxotrophic phenotype for cysteine in CMM-GGPs (Fig .
3B and E) . However, Catlin reported that 90% (52 of 57) of N .
meningitidis clinical isolates were not auxotrophic for cysteine
on synthetic medium (MCDA) that did not contain cysteine and
-glutamyl-cysteinyl
peptides (5) . We also confirmed that H44/76 could
grow on MCDA (data not shown), and the genes of enzymes necessary for
cysteine synthesis from glycine can be found in the whole-genome
sequence of N . meningitidis strain MC58 (24;
http://www.tigr.org/tigr-scripts/CMR2/CMRHomePage.spl) . The
discrepancy may be due to the differences between the concentrations
of the amino acids in MCDA and CMM; the concentrations of three amino
acids (L-glutamate, L-glycine, and
L-arginine) in MCDA are
1,000-,
285-, and 28-fold higher than those in CMM (4, 5) .
It is known that in bacteria the way of utilizing nutrients at
micromolar (growth rate-limiting) concentrations is different from
that at millimolar concentrations (19) and that natural
environments for bacteria are generally nutrient limited (10) .
Actually, the concentration of cysteine is very limited (<1 µM)
in CSF, due to its neurotoxicity (9, 12,
15, 26), compared with that in
rat serum (
64
µM) (12, 28) . These facts may
imply that N . meningitidis strain H44/76 cannot grow under
conditions of limited nutrients, like those in CMM, even if the
synthetic pathway for cysteine exists, probably because such a
pathway may not work efficiently under these conditions .
The growth failure of H44/76 in CMM-GGPs without
-glutamyl
peptides was suppressed by supplying GSH,
-Glu-Cys,
or Cys (Fig . 3C, D, and E) . The
ggt
derivative HT1089 could not grow in CMM and CMM-GGPs (Fig.
3A and B), but supplying cysteine restored growth
(Fig . 3E, G, and H) . As GGT catalyzes the hydrolysis of
-glutamyl
compounds, H44/74 must utilize cysteine hydrolyzed from
-glutamyl-cysteinyl
peptides for its growth in nutrient-limited environments, with
the cooperation of other peptidases, as shown in E . coli (22) .
N . meningitidis multiplies in CSF (Fig . 2B),
where the amount of cysteine is very limited but certain amounts of
-glutamyl-cysteinyl
peptides are present (7, 17) . We
speculate that one of the physiological functions of the ggt
gene in N . meningitidis is to supply enough cysteine for
growth in CSF .
N . meningitidis strain H44/76 grew well in CMM (Fig . 3A),
where the concentration of total free cysteine should be 4 µM
if
-glutamyl-cysteinyl
peptides are completely hydrolyzed . Theoretically, the external
addition of 4 µM cysteine would suppress the growth failure of HT1089
in CMM, but 20 µM cysteine was required for complete suppression
(Fig . 3G and H) . The most probable explanation for
the discrepancy is that the uptake of cysteine is less efficient than
that of
-glutamyl-
cysteinyl peptides .
The growth of the
ggt
strain in rat CSF was very slow until 8 h of incubation but seemed to
be faster after that time (Fig . 2B), which was
different from the results with HT1089 in CMM (Fig . 3A) .
We do not know the exact reason for the difference . It may be due to
the degradation of proteins in the CSF by long-term incubation at
37°C (15) and their utilization by bacteria for
growth . Alternatively, it is also possible that N . meningitidis
has some other inducible pathways for the promotion of growth
under the conditions present in rat CSF .
To our knowledge, this is the first report of the physiological role of meningococcal GGT, which has been used as a laboratory marker for the identification of N . meningitidis . Although it remains unclear whether the growth advantage for meningococcal multiplication in CSF is related to meningococcal pathogenicity in vivo, our observations in this study suggest the possible involvement of N . meningitidis GGT in bacterial virulence .
Nucleotide sequence accession number. The nucleotide sequence of the ggt allele in H44/76 has been deposited in the DDBJ/EMBL/GenBank nucleotide database under accession number AB089320 .
| ACKNOWLEDGMENTS |
|---|
This work was supported by grants from the Ministry of Health,
Welfare and Labor of Japan . H.T . was also supported by a grant from
the Ministry of Education, Culture, Sports, Science and Technology of
Japan (grant no . 13770142) .
| FOOTNOTES |
|---|
* Corresponding author . Mailing address: Toyama 1-23-1,
Shinjuku-ku, Tokyo 162-8640, Japan . Phone: 81-3-5285-1111 . Fax: 81-3-5285-1171 .
E-mail: haruwata@nih.go.jp.
| REFERENCES |
|---|
What Is Cell Biology?,
What Is Rhizobia?,
What Is Growth Medium?,
What Is Pcr?,
What Is Bioassay?,
c,
Microorganisms,
n,
Bacteria,
i,
Microbe,
n,
Microorganism,
i,
Microbes,
n,
Meningococcus,
i,
Acinetobacter,
r,
Antibiotics,
s,
Staphylococcus,
i,
Campylobacter,
a,
Bacteriophages,
r,
Escherichia coli,
e,
Staphylococcus aureus,
c,
Escherichia coli,
i,
Streptococci,
i,
Beta lactamase,
n,
Clostridia,
a,
Streptococcal,
o,
Microorganisms,
i,
Haemophilus,
e,
Cholera,
c,
Antibiotics,
c,
Salmonella typhimurium,
n,
Escherichia coli,
s,
Rhizobacterium,
a,
Minimum inhibiting concentration
© 2005
Transgalactic Ltd (manufacturer of Bioscreen C software) |
Privacy Statement | P.O. Box
1393, 00101 Helsinki, Finland,
Last modified: May 25, 2005
| ||||||